|
Brief Reports
Citations 181-190 of 1234 total displayed.
|
Past content
(since Jul 1999):
|
EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma
- Hanneke C. Kluin-Nelemans, Jules L. Coenen, James E. Boers, Gustaaf W. van Imhoff, and Stefano Rosati
Blood 2008; 112: 1039-1041.
[Abstract]
[Full text]
[PDF]
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab
- Roberto Stasi, Nichola Cooper, Giovanni Del Poeta, Elisa Stipa, Maria Laura Evangelista, Elisabetta Abruzzese, and Sergio Amadori
Blood 2008; 112: 1147-1150.
[Abstract]
[Full text]
[PDF]
Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors
- Shannon L. Meeks, John F. Healey, Ernest T. Parker, Rachel T. Barrow, and Pete Lollar
Blood 2008; 112: 1151-1153.
[Abstract]
[Full text]
[PDF]
Angiopoietin-1 mediates the proangiogenic activity of the bone morphogenic protein antagonist Drm
- Stefania Mitola, Emanuela Moroni, Cosetta Ravelli, German Andres, Mirella Belleri, and Marco Presta
Blood 2008; 112: 1154-1157.
[Abstract]
[Full text]
[PDF]
Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura
- Jin Yu, Susanne Heck, Vivek Patel, Jared Levan, Yu Yu, James B. Bussel, and Karina Yazdanbakhsh
Blood 2008; 112: 1325-1328.
[Abstract]
[Full text]
[PDF]
Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin
- Maciej Bogdan Maniecki, Henrik Hasle, Lennart Friis-Hansen, Birgitte Lausen, Ove Juul Nielsen, Knud Bendix, Søren Kragh Moestrup, and Holger Jon Møller
Blood 2008; 112: 1510-1514.
[Abstract]
[Full text]
[PDF]
Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival
- Sung W. Choi, Carrie L. Kitko, Thomas Braun, Sophie Paczesny, Gregory Yanik, Shin Mineishi, Oleg Krijanovski, Dawn Jones, Joel Whitfield, Kenneth Cooke, Raymond J. Hutchinson, James L. M. Ferrara, and John E. Levine
Blood 2008; 112: 1539-1542.
[Abstract]
[Full text]
[PDF]
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
- Constantine S. Tam, Hagop Kantarjian, Guillermo Garcia-Manero, Gautam Borthakur, Susan O'Brien, Farhad Ravandi, Jenny Shan, and Jorge Cortes
Blood 2008; 112: 516-518.
[Abstract]
[Full text]
[PDF]
Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1
- Martin Stern, Loredana Ruggeri, Marusca Capanni, Antonella Mancusi, and Andrea Velardi
Blood 2008; 112: 708-710.
[Abstract]
[Full text]
[PDF]
Restrictive usage of monoclonal immunoglobulin  light chain germline in POEMS syndrome
- Daijiro Abe, Chiaki Nakaseko, Masahiro Takeuchi, Hiroaki Tanaka, Chikako Ohwada, Emiko Sakaida, Yusuke Takeda, Kayo Oda, Shinichi Ozawa, Naomi Shimizu, Shinichi Masuda, Ryuko Cho, Miki Nishimura, Sonoko Misawa, Satoshi Kuwabara, and Yasushi Saito
Blood 2008; 112: 836-839.
[Abstract]
[Full text]
[PDF]
|
|
